


 Cite this: *RSC Adv.*, 2026, **16**, 8693

## Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

 Marwa N. Rahimi,<sup>ab</sup> Jo-Anne Pinson,<sup>ab</sup> Joseph Hilton-Proctor,<sup>ab</sup> Jessica Van Zuylekom,<sup>bc</sup> Benjamin Blyth,<sup>bc</sup> Peter D. Roselt<sup>ab</sup> and Mohammad B. Haskali<sup>\*ab</sup>

DOI: 10.1039/d6ra90008a

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

 Correction for 'Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting' by Marwa N. Rahimi *et al.*, *RSC Adv.*, 2026, **16**, 2123–2132, <https://doi.org/10.1039/D5RA08789A>.

The authors regret that chemical structures in Fig. 1 were incorrectly shown in the original article. The amended Fig. 1 is shown below with *N*-methylation of the C-terminal naphthylalanine residue for structures GA4 and GA13.



<sup>a</sup>Department of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia. E-mail: mo.haskali@petermac.org

<sup>b</sup>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia

<sup>c</sup>Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Victoria 3000, Australia




Fig. 1 Chemical structures of CCK<sub>2</sub>R targeting peptides CP04, GA4, and GA13.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

